UHPLC-HRMS data from non-targeted screening for biotransformation products of cytostatic drug imatinib

Imatinib is a selective tyrosine kinase inhibitor used to treat chronic myeloid leukemia. It enters the environment by excretion from the body through urine and feces and is transferred with wastewater to a wastewater treatment plant. There, it can be degraded by activated sludge, forming a number o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tkalec, Žiga, Negreira, Noelia, López de Alda, Miren, Barceló, Damiá, Kosjek, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897666/
https://www.ncbi.nlm.nih.gov/pubmed/35257019
http://dx.doi.org/10.1016/j.dib.2022.107991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897666/
https://www.ncbi.nlm.nih.gov/pubmed/35257019
http://dx.doi.org/10.1016/j.dib.2022.107991

Ejemplares similares